Stock listing
Sprint Bioscience Ab
Selected listing: A14NY2 · LS · EUR · DE
Sprint Bioscience Ab (Lang & Schwarz: A14NY2), Health Technology. Latest release Jul 23, 2026: Sprint Bioscience announces agreement with Lilly TuneLab…
- Ticker
- Lang & Schwarz: A14NY2
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- Lang & Schwarz
- Currency
- EUR
Latest news from Sprint Bioscience Ab
Sprint Bioscience announces agreement with Lilly TuneLab to accelerate drug development
July 23, 2026
Sprint Bioscience (publ) announces that Aktiespararna initiates commissioned research coverage of the company
June 4, 2026
Sprint Bioscience completes strategic STK25 evaluation; continued focus on the primary indication
April 16, 2026
Sprint Bioscience appoints Jenni Björnulfson as CFO
April 1, 2026
Sprint Bioscience sells the TREX1 program to Gilead
November 24, 2025
Research Sprint Bioscience Ab
Sprint Bioscience Ab company profile
View the public company page for Sprint Bioscience Ab on 6ix.
Sprint Bioscience Ab news
Read company news and market updates connected to Sprint Bioscience Ab.
Sprint Bioscience Ab investor events
Find investor webinars, events, and replay context for Sprint Bioscience Ab.
Alternate listings
SPRINT:OMXSTO
SE · SEK
Alternate listing for Sprint Bioscience Ab; the primary context on this page is A14NY2:LS.
5JA1:GETTEX
DE · EUR
Alternate listing for Sprint Bioscience Ab; the primary context on this page is A14NY2:LS.
A14NY2:LSX
DE · EUR
Alternate listing for Sprint Bioscience Ab; the primary context on this page is A14NY2:LS.
5JA1:MUN
DE · EUR
Alternate listing for Sprint Bioscience Ab; the primary context on this page is A14NY2:LS.
5JA1:FWB
DE · EUR
Alternate listing for Sprint Bioscience Ab; the primary context on this page is A14NY2:LS.
5JA1:SWB
DE · EUR
Alternate listing for Sprint Bioscience Ab; the primary context on this page is A14NY2:LS.